



PharmIdeia is Latvia based pharmaceutical company dedicated to the research, development and commercialization of hospital, women health and anti-cancer drugs with main R&D and production competence in sterile formulations.

PharmIdeia is the only company in the Baltic region providing sterile and freeze-dried drugs manufacturing at a world class quality, which is granted by the GMP certificate and various international quality inspections.

PharmIdeia product portfolio contains self-developed generic products which are being registered in more than 50 countries worldwide.

Our services include contract manufacturing, technology development, validation, elaboration of specifications and test methods of sterile products, stability studies.

## Atosiban 37.5 mg/5 ml concentrate for solution for infusion

## Atosiban 6.75 mg/0.9 ml solution for injection

**Therapeutic indications.** Atosiban PharmIdeia is indicated to delay imminent preterm birth in pregnant adult women with:

- a gestational age from 24 until 33 completed weeks
- regular uterine contractions of at least 30 seconds duration at a rate of  $\geq 4$  per 30 minutes

Atosiban, is an oxytocin/vasopressin antagonist that blocks the action of oxytocin and is able to prevent uterine contractions and relax the uterus.

### Posology

Step	Regimen	Injection/infusion rate	Atosiban dose
1	0.9 ml intravenous bolus injection given over 1 minute	not applicable	6.75 mg
2	3 hours intravenous loading infusion	24 ml/hour (300 $\mu$ g/min)	54 mg
3	up to 45 hours subsequent intravenous infusion	8 ml/hour (100 $\mu$ g/min)	up to 270 mg



Preterm birth is a widespread, serious medical and social problem with a worldwide incidence which ranges between 6% and 15%.

Atosiban has a specific mode of action – inhibition of oxytocin-induced uterine contractions by blocking of OTRs in the uterus. The onset of uterus relaxation following Atosiban is rapid, uterine contractions are significantly reduced within 10 minutes, achieving stable uterine quiescence.

**Atosiban is recommended by EBCOG\* as a first-line tocolytic**

### Clinical advantages:

- efficiency similar to Ca channel blockers
- less common maternal side effects vs other tocolytics

### Suitable for:

- pregnancy with cardiovascular disease
- pregnancy with diabetes
- multiple pregnancy

**Pharmacotherapeutic group:** Other gynecologicals

**ATC code:** G02CX01

Shelf life – 3 years

Store in a refrigerator (2–8 °C)

**Manufacturer:** PharmIdeia SIA, 4 Rupnicu Str., Olaine, LV 2114, Latvia  
www.pharmideia.lv  
pharmideia@pharmideia.lv

